DekaBank Deutsche Girozentrale Purchases 5,425 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• DekaBank Deutsche Girozentrale increased its stake in Thermo Fisher Scientific by 0.7% during the second quarter, owning a total of 772,643 shares worth approximately $317.5 million.
• Insiders at Thermo Fisher Scientific sold a total of 30,066 shares valued at over $14 million in the last 90 days, with the chief accounting officer experiencing a 14.24% decrease in their position after selling 385 shares.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36, beating expectations, and has set guidance for Q3 2025 EPS in the range of 5.460-5.510.

DekaBank Deutsche Girozentrale raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 772,643 shares of the medical research company's stock after purchasing an additional 5,425 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.20% of Thermo Fisher Scientific worth $317,498,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Journey Advisory Group LLC purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at $2,611,000. Canvas Wealth Advisors LLC increased its position in Thermo Fisher Scientific by 170.2% during the 2nd quarter. Canvas Wealth Advisors LLC now owns 1,394 shares of the medical research company's stock valued at $565,000 after purchasing an additional 878 shares during the period. Lyell Wealth Management LP increased its position in Thermo Fisher Scientific by 4.3% during the 2nd quarter. Lyell Wealth Management LP now owns 32,114 shares of the medical research company's stock valued at $13,021,000 after purchasing an additional 1,333 shares during the period. Accretive Wealth Partners LLC increased its position in Thermo Fisher Scientific by 1.3% during the 2nd quarter. Accretive Wealth Partners LLC now owns 3,248 shares of the medical research company's stock valued at $1,317,000 after purchasing an additional 41 shares during the period. Finally, Cidel Asset Management Inc. increased its position in Thermo Fisher Scientific by 14.0% during the 2nd quarter. Cidel Asset Management Inc. now owns 1,560 shares of the medical research company's stock valued at $633,000 after purchasing an additional 191 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $539.05 on Monday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company's 50-day moving average is $495.74 and its 200 day moving average is $448.98. The company has a market capitalization of $203.55 billion, a price-to-earnings ratio of 31.18, a price-to-earnings-growth ratio of 2.93 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TMO shares. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. HSBC reaffirmed a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating on the stock. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $589.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.